Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery.

Biodegradable polymer and particulate carriers have been shown to be of considerable potential for the delivery of peptides, proteins and DNA in animal models. In the context of vaccine delivery to the upper and lower respiratory tracts, the use of mucoadhesive agents offers a strategy for the facilitation of increased residence time and increased vaccine efficacy. Additional concerns addressed here include the potential of uptake of vaccine formulations by the primary olfactory nerves in the nasal cavity, effective delivery to the lung, strategies to maximise the immunopotentiation of candidate vaccine formulations, as well as the evaluation of animal models and interpretation of engendered immune responses in terms of antigen-specific antibody production. Experimental data are presented that demonstrate the potential of muco- and bioadhesive agents in combination with liposomes for intranasal (i.n.) delivery of tetanus toxoid in mice. A delivery system utilising chitosan for the formulation of microspheres by the spray-drying method is described and assessed for intranasal vaccine delivery, and porous particles with potential for pulmonary administration are also outlined.

[1]  V E Schijns,et al.  Immunological concepts of vaccine adjuvant activity. , 2000, Current opinion in immunology.

[2]  J. Eldridge,et al.  Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. , 1989, Advances in experimental medicine and biology.

[3]  P. Ogra Effect of tonsillectomy and adenoidectomy on nasopharyngeal antibody response to poliovirus. , 1971, The New England journal of medicine.

[4]  M. D. de Jong,et al.  Herd immunity after vaccination: how to quantify it and how to use it to halt disease. , 2001, Vaccine.

[5]  R. Chanock,et al.  Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus , 1983, Infection and immunity.

[6]  N. Restifo Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. , 2000, Current opinion in immunology.

[7]  H. Alpár,et al.  Intranasal vaccination against plague, tetanus and diphtheria. , 2001, Advanced drug delivery reviews.

[8]  H. Lassmann,et al.  Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials , 1999, Nature Medicine.

[9]  C. Caruso,et al.  Major histocompatibility complex regulation of cytokine production. , 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[10]  H. Alpár,et al.  Current status of DNA vaccines and their route of administration. , 2002, Critical reviews in therapeutic drug carrier systems.

[11]  C. Dibble,et al.  The role of international environmental agreements in metered-dose inhaler technology changes. , 1999, The Journal of allergy and clinical immunology.

[12]  H. Merkle,et al.  Cationic stearylamine-containing biodegradable microparticles for DNA delivery , 2004, Journal of microencapsulation.

[13]  M. R. Brown,et al.  Antimicrobial properties of liposomal polymyxin B. , 1999, The Journal of antimicrobial chemotherapy.

[14]  G. Scheuch,et al.  In vitro testing of two formoterol dry powder inhalers at different flow rates. , 2002, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[15]  R. Herrero-Vanrell,et al.  Enhancement of the mydriatic response to tropicamide by bioadhesive polymers. , 2000, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[16]  C. Ehrhardt,et al.  Large Porous Particle Impingement on Lung Epithelial Cell Monolayers—Toward Improved Particle Characterization in the Lung , 2003, Pharmaceutical Research.

[17]  M. Svartengren,et al.  Inhalation and deposition of nebulized sodium cromoglycate in two different particle size distributions in children with asthma , 2002, Pediatric pulmonology.

[18]  R. Lynch,et al.  Differential Induction of Mucosal and Systemic Antibody Responses in Women After Nasal, Rectal, or Vaginal Immunization: Influence of the Menstrual Cycle1 , 2002, The Journal of Immunology.

[19]  P. Veski,et al.  Evaluation of microcrystalline chitosans for gastro-retentive drug delivery. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[20]  J. Fowler,et al.  Peristomal allergic contact dermatitis due to Gantrez in Stomahesive paste. , 2000, Journal of the American Academy of Dermatology.

[21]  R. Roden,et al.  Nasal Immunization of Mice with Human Papillomavirus Type 16 Virus-Like Particles Elicits Neutralizing Antibodies in Mucosal Secretions , 1998, Journal of Virology.

[22]  Mandip Singh,et al.  Evaluation of the Malvern Spraytec with inhalation cell for the measurement of particle size distribution from metered dose inhalers. , 2004, Journal of pharmaceutical sciences.

[23]  Y. Makino,et al.  Mucoadhesive beclomethasone microspheres for powder inhalation: their pharmacokinetics and pharmacodynamics evaluation. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[24]  Vincent W. Bramwell,et al.  Liposome/DNA complexes coated with biodegradable PLA improve immune responses to plasmid encoding hepatitis B surface antigen , 2002, Immunology.

[25]  Y. Makino,et al.  Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[26]  R. Kradin,et al.  The antigen-presenting activities of Ia+ dendritic cells shift dynamically from lung to lymph node after an airway challenge with soluble antigen , 1995, The Journal of experimental medicine.

[27]  J. Brussee,et al.  Preparation and NMR characterization of highly substitutedN-trimethyl chitosan chloride , 1998 .

[28]  A. Gebert,et al.  M cells at locations outside the gut. , 1999, Seminars in immunology.

[29]  I. Lorenz,et al.  The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. , 2003, Vaccine.

[30]  F. Marincola,et al.  Cancer therapy using a self-replicating RNA vaccine , 1999, Nature Medicine.

[31]  J. Holmgren,et al.  Nasal and Vaginal Vaccinations Have Differential Effects on Antibody Responses in Vaginal and Cervical Secretions in Humans , 2001, Infection and Immunity.

[32]  J. Henriksson,et al.  Uptake of cobalt from the nasal mucosa into the brain via olfactory pathways in rats. , 2003, Toxicology letters.

[33]  Hugh D C Smyth,et al.  The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. , 2003, Advanced drug delivery reviews.

[34]  H. Staats,et al.  Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. , 1997, AIDS research and human retroviruses.

[35]  A. Almeida,et al.  Microsphere absorption by the nasal mucosa of the rat. , 1994, Journal of drug targeting.

[36]  M Keller,et al.  Innovations and perspectives of metered dose inhalers in pulmonary drug delivery. , 1999, International journal of pharmaceutics.

[37]  Vincent W. Bramwell,et al.  Stimulation of spleen cells in vitro by nanospheric particles containing antigen. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[38]  Preparation of microcapsules from complex coacervation of Gantrez-gelatin. III. Bioavailability of nitrofurantoin microcapsules. , 1988, Journal of microencapsulation.

[39]  Clark,et al.  Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52 , 1998, Immunology.

[40]  Krishnendu Roy,et al.  Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy , 1999, Nature Medicine.

[41]  J. Mcghee,et al.  Peyer's patches are required for oral tolerance to proteins , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  H. Junginger,et al.  N-Trimethylated Chitosan Chloride (TMC) Improves the Intestinal Permeation of the Peptide Drug Buserelin In Vitro (Caco-2 Cells) and In Vivo (Rats) , 2004, Pharmaceutical Research.

[43]  M. Russell,et al.  Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system , 1997, Immunologic research.

[44]  P. Brandtzaeg,et al.  Mucosal Immunology of the Upper Airways: An Overview a , 1997, Annals of the New York Academy of Sciences.

[45]  J. Lanciego,et al.  Multiple neuroanatomical tracing in primates. , 1998, Brain research. Brain research protocols.

[46]  David M. Mosser,et al.  Cutting Edge: Biasing Immune Responses by Directing Antigen to Macrophage Fcγ Receptors1 , 2002, The Journal of Immunology.

[47]  D. Bout,et al.  Intranasal Immunization with Toxoplasma gondii SAG1 Induces Protective Cells into Both NALT and GALT Compartments , 2000, Infection and Immunity.

[48]  H. Staats,et al.  Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). , 1996, Journal of immunology.

[49]  Gerrit Borchard,et al.  Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. , 2004, Vaccine.

[50]  Waldrep Jc New aerosol drug delivery systems for the treatment of immune-mediated pulmonary diseases. , 1998 .

[51]  A. Sabin Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[52]  R. Langer,et al.  Formulation and Physical Characterization of Large Porous Particles for Inhalation , 1999, Pharmaceutical Research.

[53]  N. Lycke From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1‐DD/ISCOM , 2004, Cellular microbiology.

[54]  A. Bernkop‐Schnürch,et al.  Thiolated chitosans: development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[55]  J. Hanes,et al.  New polymeric carriers for controlled drug delivery following inhalation or injection. , 2002, Biomaterials.

[56]  J. Kaldor,et al.  The causal link between human papillomavirus and invasive cervical cancer: A population‐based case‐control study in colombia and spain , 1992, International journal of cancer.

[57]  A. Almeida,et al.  Nasal delivery of vaccines. , 1996, Journal of drug targeting.

[58]  R. Tharanathan,et al.  Chitin — The Undisputed Biomolecule of Great Potential , 2003, Critical reviews in food science and nutrition.

[59]  F. Szoka,et al.  Efficiency of Cytoplasmic Delivery by pH-Sensitive Liposomes to Cells in Culture , 1990, Pharmaceutical Research.

[60]  B. Murphy,et al.  Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. , 1995, Vaccine.

[61]  W. Lencer,et al.  Membrane traffic and the cellular uptake of cholera toxin. , 1999, Biochimica et biophysica acta.

[62]  D A Groneberg,et al.  Fundamentals of pulmonary drug delivery. , 2003, Respiratory medicine.

[63]  Arturo Casadevall,et al.  Antibody-mediated regulation of cellular immunity and the inflammatory response. , 2003, Trends in immunology.

[64]  Liposomes as immunological adjuvants , 1974 .

[65]  H. Adami,et al.  Infections as a major preventable cause of human cancer , 2000, Journal of internal medicine.

[66]  Gerene M. Denning,et al.  Inhibition of Ca2+ Signaling by Mycobacterium tuberculosisIs Associated with Reduced Phagosome–Lysosome Fusion and Increased Survival within Human Macrophages , 2000, The Journal of experimental medicine.

[67]  J. Mcghee,et al.  Cutting Edge: The Mucosal Adjuvant Cholera Toxin Redirects Vaccine Proteins into Olfactory Tissues , 2000, The Journal of Immunology.

[68]  Y. Oh,et al.  Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus‐like particle vaccine in thermosensitive mucoadhesive delivery systems , 2003, Journal of medical virology.

[69]  Y. Kawashima,et al.  Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. , 2003, Journal of Controlled Release.

[70]  P. Barkvoll,et al.  Antiplaque, antibacterial, and anti-inflammatory properties of triclosan mouthrinses in combination with zinc citrate or polyvinylmethylether maleic acid (PVM-MA) copolymer. , 1996, European journal of oral sciences.

[71]  H. Alpar,et al.  Effectiveness of liposomes as adjuvants of orally and nasally administered tetanus toxoid , 1992 .

[72]  M. Wirth,et al.  Gantrez AN as a new polymer for the preparation of ligand-nanoparticle conjugates. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[73]  K. Uekama,et al.  Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats. , 1995, Journal of pharmaceutical sciences.

[74]  C. Lehr,et al.  Lectin-mediated drug delivery: the second generation of bioadhesives. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[75]  H. Tamura,et al.  Immunological aspects of chitin and chitin derivatives administered to animals. , 1999, EXS.

[76]  H. Junginger,et al.  Effect of the degree of quaternization of N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). , 1999, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[77]  M. Gamble,et al.  A comparative study on the pulmonary delivery of tobramycin encapsulated into liposomes and PLA microspheres following intravenous and endotracheal delivery , 1995 .

[78]  G. Raghava,et al.  Measurement and computation of murine interleukin-4 and interferon-gamma by exploiting the unique abilities of these lymphokines to induce the secretion of IgG1 and IgG2a. , 1993, Journal of immunoassay.

[79]  H. Junginger,et al.  Oral drug absorption enhancement by chitosan and its derivatives. , 2001, Advanced drug delivery reviews.

[80]  J. Eyles,et al.  Tissue distribution of radioactivity following intranasal administration of radioactive microspheres , 2001, The Journal of pharmacy and pharmacology.

[81]  K. Uekama,et al.  Cyclodextrins in peptide and protein delivery. , 1999, Advanced drug delivery reviews.

[82]  H. Junginger,et al.  Effects of N-trimethyl chitosan chloride, a novel absorption enhancer, on caco-2 intestinal epithelia and the ciliary beat frequency of chicken embryo trachea. , 1999, International journal of pharmaceutics.

[83]  L. Frati,et al.  CD44 triggering enhances human NK cell cytotoxic functions. , 1994, Journal of immunology.

[84]  L. Huang,et al.  DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. , 1994, Biochimica et biophysica acta.

[85]  M. Parry-Billings,et al.  The inhalers of the future? A review of dry powder devices on the market today. , 2003, Pulmonary pharmacology & therapeutics.

[86]  J. Holmgren,et al.  Antibody Responses in the Lower Respiratory Tract and Male Urogenital Tract in Humans after Nasal and Oral Vaccination with Cholera Toxin B Subunit , 1999, Infection and Immunity.

[87]  Preparation of microcapsules from complex coacervation of Gantrez-gelatin. II. In vitro dissolution of nitrofurantoin microcapsules. , 1987, Journal of microencapsulation.

[88]  L. Hyland,et al.  Nasal-Associated Lymphoid Tissue Is a Site of Long-Term Virus-Specific Antibody Production following Respiratory Virus Infection of Mice , 2001, Journal of Virology.

[89]  J. Tsibouklis,et al.  Polymeric microspheres for drug delivery to the oral cavity: an in vitro evaluation of mucoadhesive potential. , 2003, Journal of pharmaceutical sciences.

[90]  J. Holmgren,et al.  Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina , 1997, Infection and immunity.

[91]  A. Velardi,et al.  Hyaluronate is costimulatory for human T cell effector functions and binds to CD44 on activated T cells. , 1994, Journal of immunology.

[92]  J. Biewenga,et al.  The role of nasopharyngeal lymphoid tissue. , 1992, Immunology today.

[93]  H. Alpár,et al.  Oral Plasmid DNA Delivery Systems for Genetic Immunisation , 2003, Journal of drug targeting.

[94]  G. Gregoriadis,et al.  Liposome-mediated DNA vaccination: the effect of vesicle composition. , 2001, Vaccine.

[95]  Gerrit Borchard,et al.  The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro , 1996 .

[96]  R. Rappuoli,et al.  Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines , 2003, Expert review of vaccines.

[97]  Y Wang,et al.  Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[98]  Y. Capan,et al.  Preparation and Characterization of Poly (D,L-Lactide-Co-Glycolide) Microspheres for Controlled Release of Poly(L-Lysine) Complexed Plasmid DNA , 1999, Pharmaceutical Research.

[99]  A. Gebert,et al.  Kinetics of particle uptake in the domes of Peyer's patches. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[100]  G. Scheuch,et al.  In vitro and in vivo dose delivery characteristics of large porous particles for inhalation. , 2002, International journal of pharmaceutics.

[101]  Lisbeth Illum,et al.  Chitosan as a Novel Nasal Delivery System for Peptide Drugs , 1994, Pharmaceutical Research.

[102]  Hans E. Junginger,et al.  Mucoadhesive Polymers in Peroral Peptide Drug Delivery. VI. Carbomer and Chitosan Improve the Intestinal Absorption of the Peptide Drug Buserelin In Vivo , 1996, Pharmaceutical Research.

[103]  J. Eyles,et al.  Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume. , 1999, International journal of pharmaceutics.

[104]  R. Muzzarelli,et al.  Biochemistry, histology and clinical uses of chitins and chitosans in wound healing. , 1999, EXS.

[105]  P. Brandtzaeg,et al.  Human nasal mucosa contains antigen-presenting cells of strikingly different functional phenotypes. , 2004, American journal of respiratory cell and molecular biology.

[106]  H. Alpar,et al.  Do interactions with phospholipids contribute to the prolonged retention of polypeptides within the lung , 1996 .

[107]  L. Lunsford,et al.  Tissue Distribution and Persistence in Mice of Plasmid DNA Encapsulated in a PLGA-Based Microsphere Delivery Vehicle , 2000, Journal of drug targeting.

[108]  S. Kato,et al.  Strain-dependent antibody response induced by DNA immunization. , 2000, Immunology letters.

[109]  S. Rossi,et al.  Assessment of chitosan derivatives as buccal and vaginal penetration enhancers. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[110]  G. Icardi,et al.  Anamnestic response to administration of purified non-adsorbed hepatitis B surface antigen in healthy responders to hepatitis B vaccine with long-term non-protective antibody titres. , 2002, Vaccine.

[111]  M. Russell,et al.  Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit , 1993, Infection and immunity.

[112]  Vincent W. Bramwell,et al.  Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration. , 2001, Vaccine.

[113]  Lisbeth Illum,et al.  Absorption Enhancers for Nasal Drug Delivery , 2003, Clinical pharmacokinetics.

[114]  P. Hogarth,et al.  Cutting Edge: Identification of the Mouse IgG3 Receptor: Implications for Antibody Effector Function at the Interface Between Innate and Adaptive Immunity , 1998, The Journal of Immunology.

[115]  P. Holt,et al.  A contiguous network of dendritic antigen-presenting cells within the respiratory epithelium. , 1990, International archives of allergy and applied immunology.

[116]  H. Merkle,et al.  Encapsulation of plasmid DNA in PLGA-stearylamine microspheres: a comparison of solvent evaporation and spray-drying methods. , 2003, Journal of microencapsulation.

[117]  Y. Kawashima,et al.  Enteral Absorption of Insulin in Rats from Mucoadhesive Chitosan-Coated Liposomes , 1996, Pharmaceutical Research.

[118]  F. Szoka,et al.  Mechanism of oligonucleotide release from cationic liposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[119]  D. D. Ourth Neutralization of diphtheria toxin by human immunoglobulin classes and subunits. , 1974, Immunochemistry.

[120]  G. Smaldone,et al.  Effect of tubing deposition, breathing pattern, and temperature on aerosol mass distribution measured by cascade impactor. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[121]  S. Demotz,et al.  Trachea, Lung, and Tracheobronchial Lymph Nodes Are the Major Sites Where Antigen-Presenting Cells Are Detected after Nasal Vaccination of Mice with Human Papillomavirus Type 16 Virus-Like Particles , 2002, Journal of Virology.

[122]  G. P. Martin,et al.  Transition to CFC-free metered dose inhalers--into the new millennium. , 2000, International journal of pharmaceutics.

[123]  M. Lubeck,et al.  Induction of mouse IgG2a- and IgG3-dependent cellular cytotoxicity in human monocytic cells (U937) by immune interferon. , 1984, Cancer research.

[124]  A. Mitra,et al.  Chitosans as nasal absorption enhancers of peptides: comparison between free amine chitosans and soluble salts. , 2000, International journal of pharmaceutics.

[125]  L. Samaranayake,et al.  Experimental Oral Candidiasis in Animal Models , 2001, Clinical Microbiology Reviews.

[126]  N Lotan,et al.  Large porous particles for pulmonary drug delivery. , 1997, Science.

[127]  A. Almeida,et al.  Immune Response to Nasal Delivery of Antigenically Intact Tetanus Toxoid Associated with Poly(l‐lactic acid) Microspheres in Rats, Rabbits and Guinea‐pigs , 1993, The Journal of pharmacy and pharmacology.

[128]  T. Martonen,et al.  Factors affecting the deposition of inhaled porous drug particles. , 2002, Journal of pharmaceutical sciences.

[129]  M. J. Staruch,et al.  Genetic influences on the adjuvanticity of muramyl dipeptide in vivo. , 1982, Journal of immunology.

[130]  Véronique Préat,et al.  Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[131]  I. Maridonneau-Parini,et al.  The Mannose Receptor Mediates Uptake of Pathogenic and Nonpathogenic Mycobacteria and Bypasses Bactericidal Responses in Human Macrophages , 1999, Infection and Immunity.

[132]  H. Junginger,et al.  Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro , 1997 .

[133]  J. Eyles,et al.  Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. , 1998, Vaccine.

[134]  K. Sotlar,et al.  Life Cycle Heterogeneity in Animal Models of Human Papillomavirus-Associated Disease , 2002, Journal of Virology.

[135]  D. Yuan,et al.  The functional relevance of NK-cell-mediated upregulation of antigen-specific IgG2a responses. , 2000, Cellular immunology.

[136]  R. Condos,et al.  Lung deposition and respirable mass during wet nebulization. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[137]  H. D. Liggitt,et al.  Aerosol Delivery of Lipid:DNA Complexes to Lungs of Rhesus Monkeys , 1998, Pharmaceutical Research.